![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 08, 2024 9:36:14 PM
Since online sales resumed in December 2022, through 1Q24, a piddling total of $1,636 has been recorded on Consolidated Statement of Operations. With the 3-7 years out of date nature of significant textual information in financial reports, best guess is the minuscule revenue is from the agreement with Viaderma Distribution, Inc (formerly Biogenx, Inc.). The agreement is for Viaderma to receive 50% of gross profit plus 5% gross sales as licensing fee. Thus, the underlying online sales have been nominal to minimal. Out of pocket price point of $99, now $149, without predicted medicare/medicaid/insurance and fsa/hsa otc approval, severely limits prospective customer base. Viaderma Distribution, Inc. would be carrying inventory, if there was any, on their balance sheet.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM